Category: Prostate Cancer Treatment

Testosterone falls with age. Prostate cancer becomes more likely with age too. When the two arrive together, an old rule of thumb has said replacement therapy is off-limits after treatment. A November 2025 review analyzed hundreds of journal articles, then narrowed to 12 well-designed studies to see whether that rule still holds up. keep reading

Sixty-four appointments in a matter of months. That was one man's reality after an aggressive prostate cancer diagnosis, and it left him with strong opinions about what helps and what doesn't. His six insights cover the shock of the news, the meaning behind a rising PSA, picking the right doctors, and the value of plain communication. keep reading

Most men treated for early prostate cancer are alive five years later, whatever option they choose. So why do about 1 in 7 look back with regret? The answer has less to do with survival and more to do with side effects nobody prepared them for, and with how the decision got made in the first place. New long-term data adds urgency to that question. keep reading

For decades, a localized prostate cancer diagnosis came with two options: treat the whole gland and accept the side effects, or watch and wait. It was an all-or-nothing choice. Focal therapy changed the math. New 10-year international data shows cancer control comparable to radical prostatectomy, with far less risk to urinary and sexual function. keep reading

Why treat an entire prostate when the trouble usually starts in one spot? That question sits at the heart of focal therapy. For decades the answer was that doctors couldn't see or target the tumor precisely enough. Advances in multiparametric MRI, MRI-guided biopsy, and the index lesion concept finally changed that, opening a middle path between radical treatment and active surveillance. keep reading

Twenty-five years ago, most men diagnosed with localized prostate cancer were pointed toward one thing: surgery. Today the picture looks entirely different, with focal treatments and Active Surveillance firmly in the mainstream. The shift was not driven by fashion. It came from advanced imaging, more accurate biopsy, and long-term trial data that changed the calculus. keep reading

For decades, doctors treated testosterone as the enemy of the prostate, a hormone to be cut off at all costs. The science now tells a far more nuanced story. Testosterone does not turn healthy prostate cells cancerous, and for men living with low testosterone, replacement therapy turns out to be both safe and effective when guided by proper testing. keep reading

Focal therapy destroys a prostate tumor while leaving healthy tissue intact. But once treatment is done, how do doctors know if it worked? A structured follow-up protocol using mpMRI is the current standard. Now a newly proposed PSMA-based scoring system called PSMA-FAB is aiming to complement that approach. keep reading

What if you could eliminate a prostate cancer tumor while keeping nearly everything else intact? That's the promise of focal therapy — and it's no longer a fringe idea. Backed by stronger imaging tools and better biopsy methods, focal therapy now delivers cancer control that rivals surgery, with far fewer side effects keep reading

"You have prostate cancer." Those words hit hard — and immediately, every part of you wants it gone. At Sperling Prostate Center, we understand that. We treat both the tumor and the man behind it, balancing advanced focal therapy with attention to lifestyle, values, and what matters most to each patient. keep reading